Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

Inclusion Criteria: * History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed at MSKCC. * Potentially completely resectable hepatic metastases without current evidence of other metastatic disease. * Abdominal and pelvic CT scans and chest CT or x-ray within 6 weeks prior to registration. (MRI of abdomen may be substituted for CT of abdomen.) * Lab values within 14 days prior to registration: * WBC ≥ 3.0 K/uL * ANC \> 1.5 K/uL * Platelets ≥ 75 K/uL * Total bilirubin \< 1.5 mg/dL * INR \< 1.5 * Creatinine \< 2.0 mg/dL * HGB ≥ 9 gm/dL * Prior chemotherapy is acceptable if last dose given ≥ 3 weeks prior to registration to this study. \[Note: no chemotherapy to be given after resection of liver lesions prior to treatment on this study.\] * KPS ≥ 70% * Signed informed consent * Patient age must be \>18 Exclusion Criteria: * Prior radiation to the liver. (Prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration.) * Active infection, ascites, hepatic encephalopathy. * Prior treatment with HAI FUDR. * Female patients who are pregnant or lactating. * Subjects discovered to have ≥1+ proteinuria at baseline will undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate \<1 g of protein/24 hours to allow participation in this study. * Patients may no…